RNS Number : 4597T
Synairgen plc
15 November 2023
 

 


Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

 


Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 14 November 2023 the Board of Synairgen granted options ('Options') over 1,900,000 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.94 per cent. of the Company's issued share capital. 

Following this grant, Synairgen has 18,940,446 options in issue, representing 9.41 per cent. of the Company's issued share capital.

Certain Options were issued to the recently recruited Chief Financial Officer and Chief Medical Officer respectively, the former a Director of the Company; the later a Persons Discharging Managerial Responsibilities ('PDMR'):


Options issued      14 Nov 2023

Total options

Ordinary shares

Total interest

Percentage holding of fully diluted share capital

Directors






Joseph Colliver

750,000

750,000

-

750,000

0.34%

PDMRs






Marcin Mankowski

750,000

750,000

-

750,000

0.34%

 

 

The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 13 November 2033, subject to the achievement of appropriate performance criteria which match the criteria for the 2022 award as set out on page 23 of the 2022 annual report.

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Joseph Colliver

2.

Reason for notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans

c)

Price(s) and volume(s)

750,000 Options awarded

Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

14 November 2023

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Dr Marcin Mankowski

2.

Reason for notification

a)

Position / status

Chief Medical Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans

c)

Price(s) and volume(s)

750,000 Options awarded

Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

14 November 2023

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAEFLFEADFAA